SOD1-ALS Gene Therapy
Amyotrophic Lateral Sclerosis (SOD1 mutation)
Pre-INDDevelopment candidate selected; IND expected mid-2025
Key Facts
Indication
Amyotrophic Lateral Sclerosis (SOD1 mutation)
Phase
Pre-IND
Status
Development candidate selected; IND expected mid-2025
Company
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company focused on breaking through barriers in neurology. Its core strength lies in the TRACER™ AAV capsid discovery platform, which generates novel vectors with enhanced blood-brain barrier penetration for intravenous delivery. The company is advancing a pipeline targeting major neurological diseases, including Alzheimer's and ALS, and has established strategic partnerships to expand its platform's reach.
View full company profile